Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211178 · ClinicalTrials.gov registry record
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A clinical trial of Breast Cancer and TNBC - Triple-Negative Breast Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 900
- Enrollment target
- 12
- Study locations
NCT07211178 is a study of Breast Cancer and TNBC - Triple-Negative Breast Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 900 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT07211178, a study of Breast Cancer and TNBC - Triple-Negative Breast Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 12
- Study locations
Study Summary
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.
Conditions Studied
Interventions
- OTHER There are no interventions in this observational study.
Study Locations (12)
Illinois
- Southern Illinois Hospital Services - Carbondale
- Cancer Care Specialist of Illinois - O'Fallon
Alabama
- Birmingham Hematology Associates - Birmingham
California
- PIH Health Whittier Hospital - Whittier
Indiana
- Goshen Center for Cancer Care - Goshen
Michigan
- Trinity Health - Ann Arbor
Missouri
- Oncology Hematology Associates - Springfield
Nevada
- Cancer Care Specialist of Reno - Reno
New Jersey
- Summit Medical Group - Florham Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2033-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07211178
The ClinicalTrials.gov registry entry for NCT07211178 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which There are no interventions in this observational study. is the first listed.
NCT07211178 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Illinois, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT07211178 about?
NCT07211178 is a clinical study titled "Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies". For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are ...
What is the current status of trial NCT07211178?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2025-10-27. Estimated completion is 2033-12.
What conditions does trial NCT07211178 study?
This clinical trial studies the following conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, Early Stage Breast Cancer, HER2 + Breast Cancer, HR Positive/HER-2 Negative Breast Cancer.
What interventions are being tested in trial NCT07211178?
The interventions under investigation include: There are no interventions in this observational study. (OTHER).
Who is sponsoring clinical trial NCT07211178?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07211178 being conducted?
This trial has 12 study locations across Alabama, California, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.